P1091: Feasibility of Asct After Anti-Pd-1 Therapy for R/R Classical Hodgkin Lymphoma

Мочкин, Н Е; Sarzhevskiy, V. O.; Protopopova, Yu.V.; Демина, Е А; Mel’nichenko, VYa; Bogatyrev, VS; Samoylova, A. A.; Мамедова, А. А.; Rukavitsyn, A.; Банникова, А Е; Смирнова, Е Г; Шорохов, Н. С.

doi:10.1097/01.hs9.0000847232.50505.64

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One conference abstract from the 2022 European Hematology Association reported that the incidence of engraftment syndrome of ASCT following anti-PD-1 treatment was high (18.6%), which can cause fulminant immune-related AE (myocarditis and pneumonitis). 32 It must be noted that these findings were preliminary, and further research is required to confirm the safety of ASCT following anti-PD-1 treatment in the context of possible immune-related AE.…”

Section: Discussionmentioning

confidence: 82%

“…One conference abstract from the 2022 European Hematology Association reported that the incidence of engraftment syndrome of ASCT following anti-PD-1 treatment is high (18.6%), which can cause fulminant irAEs (myocarditis and pneumonitis). 32 It must be noted that these findings are preliminary, and further research is required to confirm the safety of ASCT following anti-PD-1 treatment in the context of possible irAEs. Previous data on anti-PD-1 monotherapy suggested that a subgroup of patients achieving an excellent response to PD-1 blockade remain disease-free for >3 years even after discontinuation of anti-PD-1 treatment and thus may be cured.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Ding

Liu

et al. 2023

haematol

View full text Add to dashboard Cite

Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, 10–25% of patients experience therapeutic failure. This prospective multicenter phase II study attempted to investigate the efficacy and safety of the combination of tislelizumab with gemcitabine and oxaliplatin (T-GemOx) in relapsed or refractory cHL (R/R cHL). Participants received 6–8 courses of gemcitabine (1 g/m2 on day 1) and oxaliplatin (100 mg/m2 on day 1) combined with tislelizumab (200 mg on day 2) at 21-day intervals, followed by tislelizumab maintenance (every 2 months for 2 years). The main outcome measure was the best complete remission rate (CRR). As of August 2022, a total of 30 patients were consecutively enrolled and provided induction therapy. The best overall response rate and CRR were 100% (95% confidence interval [CI]: 88.4–100%) and 96.7% (95% CI: 82.8–99.9%), respectively. The median duration of follow-up after initiation of T-GemOx was 15.8 months. The 12-month progression-free survival rate without autologous stem cell transplant was 96% (95% CI: 74.8–99.4%). There were 122 adverse events (AEs) recorded, of which 93.4% were grade 1 or 2. Thrombocytopenia (10%) and anemia (6.7%) were the most common grade 3 or 4 AEs. Overall, T-GemOx demonstrated promising antitumor activity with manageable toxicities as a salvage treatment for R/R cHL. A longer follow-up duration is required to determine whether maintenance therapy with tislelizumab rather than transplantation can be curative following such a highly active regimen.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 84%

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Ding

Liu

et al. 2023

haematol

View full text Add to dashboard Cite

show abstract

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Liu,

Ping,

Song

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R/R cHL patients. Methods Transplant-eligible patients with R/R cHL were enrolled and received two 14-day cycles of camrelizumab 200 mg intravenously (IV) and two 28-day cycles of camrelizumab 200 mg IV, gemcitabine 1000 mg/m2 IV, and oxaliplatin 100 mg/m2 IV on days 1 and 15. Patients with partial response (PR) or stable disease received an additional cycle of combination therapy. Those who achieved complete response (CR) or PR proceeded to autologous stem cell transplantation (ASCT). The primary endpoint was the CR rate at the end of protocol therapy before ASCT. Results Forty-two patients were enrolled. At the end of protocol therapy, the objective response rate and CR rate were 94.9% (37/39) and 69.2% (27/39) in the evaluable set, and 88.1% (37/42) and 64.3% (27/42) in the full analysis set, respectively. Twenty-nine patients (69.0%) proceeded to ASCT, and 4 of 5 patients with PR achieved CR after ASCT. After a median follow-up of 20.7 months, the 12-month progression-free survival rate was 96.6% and the 12-month overall survival rate was 100%. Grade 3 or higher treatment emergent adverse events occurred in 28.6% of patients (12/42), mainly hematological toxicity. Conclusions Camrelizumab combined with GEMOX constitutes an effective salvage therapy for R/R cHL, proving to be relatively well-tolerated and facilitating ASCT in most patients, thus promoting sustained remission. Trial registration ClinicalTrials.gov NCT04239170. Registered on January 1, 2020.

show abstract

P1091: Feasibility of Asct After Anti-Pd-1 Therapy for R/R Classical Hodgkin Lymphoma

Cited by 2 publications

References 0 publications

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Contact Info

Product

Resources

About